Bessemer Group Inc Nurix Therapeutics, Inc. Transaction History
Bessemer Group Inc
- $55.8 Billion
- Q1 2025
A detailed history of Bessemer Group Inc transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 306,003 shares of NRIX stock, worth $3.51 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
306,003
Previous 306,003
-0.0%
Holding current value
$3.51 Million
Previous $5.77 Million
36.93%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding NRIX
# of Institutions
184Shares Held
66.9MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$78.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$49.8 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$48 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$44.5 Million0.81% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.01MShares$34.5 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $540M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...